These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 17612934

  • 1. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY, Zhao Y, Anderson WF, Johnston PB.
    Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
    [Abstract] [Full Text] [Related]

  • 2. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY, Johnston PB, Burke KA, Zhao Y.
    Cancer Res; 2006 Sep 15; 66(18):9002-8. PubMed ID: 16982741
    [Abstract] [Full Text] [Related]

  • 3. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
    Luthra R, Pugh WC, Waasdorp M, Morris W, Cabanillas F, Chan PK, Sarris AH.
    Hematopathol Mol Hematol; 1998 Sep 15; 11(3-4):173-83. PubMed ID: 9844824
    [Abstract] [Full Text] [Related]

  • 4. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD, Jenson SD, Crockett DK, Schumacher JA, Elenitoba-Johnson KS, Lim MS.
    Leuk Res; 2008 Mar 15; 32(3):383-93. PubMed ID: 17720243
    [Abstract] [Full Text] [Related]

  • 5. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
    Sjostrom C, Seiler C, Crockett DK, Tripp SR, Elenitoba Johnson KS, Lim MS.
    Exp Hematol; 2007 Aug 15; 35(8):1240-8. PubMed ID: 17560012
    [Abstract] [Full Text] [Related]

  • 6. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R.
    Oncogene; 2004 Jul 15; 23(32):5426-34. PubMed ID: 15184887
    [Abstract] [Full Text] [Related]

  • 7. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 8. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F, Arnold MD, Frist AY, Pulford K.
    Clin Cancer Res; 2002 Jan 01; 8(1):240-5. PubMed ID: 11801565
    [Abstract] [Full Text] [Related]

  • 9. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R, Rassidakis GZ, Medeiros LJ, Ramdas L, Goy AH, Cutler C, Fujio Y, Kunisada K, Amin HM, Gilles F.
    Am J Pathol; 2004 Jun 01; 164(6):2251-8. PubMed ID: 15161657
    [Abstract] [Full Text] [Related]

  • 10. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
    Thornber K, Colomba A, Ceccato L, Delsol G, Payrastre B, Gaits-Iacovoni F.
    Oncogene; 2009 Jul 23; 28(29):2690-6. PubMed ID: 19503098
    [Abstract] [Full Text] [Related]

  • 11. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
    Rassidakis GZ, Sarris AH, Herling M, Ford RJ, Cabanillas F, McDonnell TJ, Medeiros LJ.
    Am J Pathol; 2001 Aug 23; 159(2):527-35. PubMed ID: 11485911
    [Abstract] [Full Text] [Related]

  • 12. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H, Gelebart P, Anand M, Lai R.
    Cell Signal; 2013 Feb 23; 25(2):381-8. PubMed ID: 23153582
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG.
    Leukemia; 2000 Sep 23; 14(9):1533-59. PubMed ID: 10994999
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H, Lange K, Nadrowitz R, Uckert W, Blankenstein T, Feller AC.
    Verh Dtsch Ges Pathol; 2003 Sep 23; 87():224-31. PubMed ID: 16888916
    [Abstract] [Full Text] [Related]

  • 19. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL).
    Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W.
    Oligonucleotides; 2003 Sep 23; 13(5):365-73. PubMed ID: 15000827
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.